PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-10.41%
Negative ROE while Drug Manufacturers - Specialty & Generic median is -0.63%. Seth Klarman would investigate if capital structure or industry issues are at play.
-8.40%
Negative ROA while Drug Manufacturers - Specialty & Generic median is -1.07%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
5.19%
ROCE exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.08%. Joel Greenblatt would look for a high return on incremental capital.
-4.39%
Negative gross margin while Drug Manufacturers - Specialty & Generic median is 45.68%. Seth Klarman would check if the firm is selling below cost.
175.14%
Margin of 175.14% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if moderate profitability can be leveraged further.
-298.58%
Negative net margin while Drug Manufacturers - Specialty & Generic median is -2.01%. Seth Klarman would see if cost cuts or revenue growth can fix losses.